207 related articles for article (PubMed ID: 17284367)
1. Methylation profile of genes CDKN2A (p14 and p16), DAPK1, CDH1, and ADAM23 in head and neck cancer.
Calmon MF; Colombo J; Carvalho F; Souza FP; Filho JF; Fukuyama EE; Camargo AA; Caballero OL; Tajara EH; Cordeiro JA; Rahal P
Cancer Genet Cytogenet; 2007 Feb; 173(1):31-7. PubMed ID: 17284367
[TBL] [Abstract][Full Text] [Related]
2. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients.
Rosas SL; Koch W; da Costa Carvalho MG; Wu L; Califano J; Westra W; Jen J; Sidransky D
Cancer Res; 2001 Feb; 61(3):939-42. PubMed ID: 11221887
[TBL] [Abstract][Full Text] [Related]
3. Patterns of gene promoter methylation in squamous cell cancer of the head and neck.
Hasegawa M; Nelson HH; Peters E; Ringstrom E; Posner M; Kelsey KT
Oncogene; 2002 Jun; 21(27):4231-6. PubMed ID: 12082610
[TBL] [Abstract][Full Text] [Related]
4. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
De Schutter H; Geeraerts H; Verbeken E; Nuyts S
Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
[TBL] [Abstract][Full Text] [Related]
5. INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck.
Weber A; Bellmann U; Bootz F; Wittekind C; Tannapfel A
Virchows Arch; 2002 Aug; 441(2):133-42. PubMed ID: 12189502
[TBL] [Abstract][Full Text] [Related]
6. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients.
Sanchez-Cespedes M; Esteller M; Wu L; Nawroz-Danish H; Yoo GH; Koch WM; Jen J; Herman JG; Sidransky D
Cancer Res; 2000 Feb; 60(4):892-5. PubMed ID: 10706101
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic abnormalities in cutaneous squamous cell carcinomas: frequent inactivation of the RB1/p16 and p53 pathways.
Murao K; Kubo Y; Ohtani N; Hara E; Arase S
Br J Dermatol; 2006 Nov; 155(5):999-1005. PubMed ID: 17034532
[TBL] [Abstract][Full Text] [Related]
8. Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma.
Nayak CS; Carvalho AL; Jeronimo C; Henrique R; Kim MM; Hoque MO; Chang S; Jiang WW; Koch W; Westra W; Sidransky D; Califano J
Laryngoscope; 2007 Aug; 117(8):1376-80. PubMed ID: 17592394
[TBL] [Abstract][Full Text] [Related]
9. The p16 (CDKN2a/INK4a) tumor-suppressor gene in head and neck squamous cell carcinoma: a promoter methylation and protein expression study in 100 cases.
Ai L; Stephenson KK; Ling W; Zuo C; Mukunyadzi P; Suen JY; Hanna E; Fan CY
Mod Pathol; 2003 Sep; 16(9):944-50. PubMed ID: 13679459
[TBL] [Abstract][Full Text] [Related]
10. Aberrant promoter hypermethylation in serum DNA from patients with silicosis.
Umemura S; Fujimoto N; Hiraki A; Gemba K; Takigawa N; Fujiwara K; Fujii M; Umemura H; Satoh M; Tabata M; Ueoka H; Kiura K; Kishimoto T; Tanimoto M
Carcinogenesis; 2008 Sep; 29(9):1845-9. PubMed ID: 18632757
[TBL] [Abstract][Full Text] [Related]
11. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
[TBL] [Abstract][Full Text] [Related]
12. DAPK1 promoter hypermethylaiton in brain metastases and peripheral blood.
Martinez-Glez V; Franco-Hernandez C; Gonzalez-Gomez P; Isla A; De Campos JM; Vaquero J; Gutierrez M; Casartelli C; Rey JA
Neoplasma; 2007; 54(2):123-6. PubMed ID: 17319784
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.
Ahmed IA; Pusch CM; Hamed T; Rashad H; Idris A; El-Fadle AA; Blin N
Cancer Genet Cytogenet; 2010 Jun; 199(2):96-100. PubMed ID: 20471512
[TBL] [Abstract][Full Text] [Related]
14. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer.
Kawamoto K; Enokida H; Gotanda T; Kubo H; Nishiyama K; Kawahara M; Nakagawa M
Biochem Biophys Res Commun; 2006 Jan; 339(3):790-6. PubMed ID: 16316628
[TBL] [Abstract][Full Text] [Related]
15. Analysis of promoter hypermethylation of death-associated protein kinase and p16 tumor suppressor genes in actinic keratoses and squamous cell carcinomas of the skin.
Tyler LN; Ai L; Zuo C; Fan CY; Smoller BR
Mod Pathol; 2003 Jul; 16(7):660-4. PubMed ID: 12861061
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
[TBL] [Abstract][Full Text] [Related]
17. p16(INK4A) promoter hypermethylation is associated with invasiveness and prognosis of oral squamous cell carcinoma in an age-dependent manner.
Su PF; Huang WL; Wu HT; Wu CH; Liu TY; Kao SY
Oral Oncol; 2010 Oct; 46(10):734-9. PubMed ID: 20729138
[TBL] [Abstract][Full Text] [Related]
18. Methylation of DAPK1 promoter: frequent but not an adverse prognostic factor in myelodysplastic syndrome.
Qian J; Yao DM; Lin J; Wang YL; Han LX; Xu WR; Wu CY
Int J Lab Hematol; 2010 Feb; 32(1 Pt 2):74-81. PubMed ID: 19196380
[TBL] [Abstract][Full Text] [Related]
19. Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach.
Schildhaus HU; Kröckel I; Lippert H; Malfertheiner P; Roessner A; Schneider-Stock R
Int J Oncol; 2005 Jun; 26(6):1493-500. PubMed ID: 15870861
[TBL] [Abstract][Full Text] [Related]
20. Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma.
Li J; El-Naggar A; Mao L
Cancer; 2005 Aug; 104(4):771-6. PubMed ID: 15959912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]